Premium
The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti‐integrin therapies
Author(s) -
Dotan Iris,
Allez Matthieu,
Danese Silvio,
Keir Mary,
Tole Swati,
McBride Jacqueline
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21601
Subject(s) - integrin , pathogenesis , inflammatory bowel disease , homing (biology) , immunology , medicine , inflammation , lymphocyte homing receptor , cell adhesion molecule , immune system , lymphocyte , disease , cancer research , cell adhesion , biology , pathology , cell , receptor , ecology , genetics
Inflammatory bowel disease (IBD) is characterized by uncontrolled inflammation in the gastrointestinal tract. The underlying pathobiology of IBD includes an increase in infiltrating gut‐homing lymphocytes. Although lymphocyte homing is typically a tightly regulated and stepwise process involving multiple integrins and adhesion molecules expressed on endothelial cells, the distinct roles of integrin‐expressing immune cells is not fully understood in the pathology of IBD. In this review, we detail the involvement of integrins expressed on specific lymphocyte subsets in the pathogenesis of IBD and discuss the current status of approved and investigational integrin‐targeted therapies.